The JS001sc-002-III-NSCLC Study is a multi-center, open-label, randomized Phase 3 clinical study led by the principal investigator Professor Lin WU from Hunan Cancer Hospital. JS001sc-002-III-NSCLC is ...
For the quarter ending December 31, 2025, management expects gross revenue of more than US$30.0 million from sales of Ryoncil ® (remestemcel-L-rknd). This represents more than 37% increase on the ...
The world-renowned, peer-reviewed, open-access Nature journal, Signal Transduction and Targeted Therapy, publishes original research on cutting-edge experimental and clinical advances on ...
The webcast of the fireside chat discussion will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days ...
8th Annual Evercore Healthcare Conference Date: Wednesday, December 3, 2025 at 8:45 am E.T. Location: Coral Gables, FL Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, ...
The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and ...
IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5 th Annual Ophthalmology ...
One-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatment ...
Jeanette Yoffe Publishes "The Traumatized and At-Risk Youth Toolbox," Her Newest Guidebook With Over 160 Attachment-Informed Interventions for Working with Kids and Families in Foster Care and Beyond ...
HYRNUO is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2). In vitro, HYRNUO inhibited the phosphorylation of HER2, downstream signaling in cancer cells with HER2 ...
Radiant Health Centers invites the public to a free World AIDS Day Policy Forum and the kickoff of its 40th Anniversary Celebration on December 1 at the Norma Herzog Community Center in Costa Mesa.
NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback